USA - NASDAQ:VTRS - US92556V1061 - Common Stock
The current stock price of VTRS is 10.36 USD. In the past month the price increased by 1.67%. In the past year, price decreased by -10.84%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 39.24 | 816.66B | ||
| JNJ | JOHNSON & JOHNSON | 18.2 | 454.86B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.56 | 255.48B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.83 | 239.64B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 12.81 | 219.77B | ||
| MRK | MERCK & CO. INC. | 9.87 | 214.76B | ||
| PFE | PFIZER INC | 7.27 | 140.15B | ||
| SNY | SANOFI-ADR | 11.52 | 123.27B | ||
| GSK | GSK PLC-SPON ADR | 7.73 | 94.25B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.02 | 93.77B | ||
| ZTS | ZOETIS INC | 23.17 | 63.86B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 48 | 42.45B |
Viatris, Inc. is a global healthcare company, which engages in the provision of healthcare and pharmaceutical products. The company is headquartered in Canonsburg, Pennsylvania and currently employs 32,000 full-time employees. The firm's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. The company produces oral solid doses, injectables, and products with complex dosage forms.
VIATRIS INC
1000 Mylan Boulevard
Canonsburg PENNSYLVANIA 15317 US
CEO: Michael Goettler
Employees: 32000
Phone: 17245141465
Viatris, Inc. is a global healthcare company, which engages in the provision of healthcare and pharmaceutical products. The company is headquartered in Canonsburg, Pennsylvania and currently employs 32,000 full-time employees. The firm's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. The company produces oral solid doses, injectables, and products with complex dosage forms.
The current stock price of VTRS is 10.36 USD.
VIATRIS INC (VTRS) has a dividend yield of 4.63%. The yearly dividend amount is currently 0.48.
VTRS has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
The next ex-dividend date for VIATRIS INC (VTRS) is August 22, 2025.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on VTRS.
The Revenue of VIATRIS INC (VTRS) is expected to decline by -6.08% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
ChartMill assigns a technical rating of 6 / 10 to VTRS. When comparing the yearly performance of all stocks, VTRS turns out to be only a medium performer in the overall market: it outperformed 49.04% of all stocks.
ChartMill assigns a fundamental rating of 4 / 10 to VTRS. While VTRS is still in line with the averages on profitability rating, there are concerns on its financial health.
Over the last trailing twelve months VTRS reported a non-GAAP Earnings per Share(EPS) of 2.41. The EPS decreased by -13% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -9.03% | ||
| ROE | -22.27% | ||
| Debt/Equity | 0.82 |
14 analysts have analysed VTRS and the average price target is 11.98 USD. This implies a price increase of 15.63% is expected in the next year compared to the current price of 10.36.
For the next year, analysts expect an EPS growth of -11.97% and a revenue growth -6.08% for VTRS